Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of KPG-121 in Combination With Enzalutamide in Adults With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2018
At a glance
- Drugs Enzalutamide (Primary) ; KPG-121 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Kangpu Biopharmaceuticals
- 15 Oct 2018 Planned End Date changed from 1 May 2020 to 1 Jun 2020.
- 15 Oct 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Oct 2019.
- 29 Aug 2018 Planned number of patients changed from 24 to 36.